Standard aseptic technique should be employed during constitution. Approximately 70% of the administered dose is recovered as unchanged meropenem in the urine over 12 hours, after which little further urinary excretion is detectable. Use in infections caused by methicillin resistant staphylococci is not recommended. There is no experience in children with altered hepatic or renal function. Refer to” Posology and method of administration” above. Nitrofurantoin or fosfomycin may also be used for Anaerobic bacteria: Actinomyces odontolyticus, Actinomyces meyeri, Bacteroides-Prevotella-Porphyromonas spp., Bacteroides fragilis, Bacteroides vulgatus, Bacteroides variabilis, Bacteroides Susceptible >14 <4 of patients with bacterial meningitis, achieving concentrations in excess of those required to inhibit most bacteria. Eur J Clin Microbiol Infect Dis. Antibiotic Spectrum Chart â Coverage for most antibiotics by class. Complicated urinary tract infections . Your email address will not be published. In 8 patients the drug was administered intravenously in a dose of 1 g every 8 hours and in 4 patients with the creatinine clearance below 50 ml/min it was administered in a dose of 1 g every 12 hours (the treatment course of 7 to 10 days). Accidental overdosage could occur during therapy, particularly in patients with renal impairment. CATEGORISATION METHOD OF ASSESSMENT ** Ceftaroline (5th Gen) does NOT cover Pseudomonas. Special warnings and precautions for use : There is some clinical and laboratory evidence of partial cross-allergenicity between other carbapenems and beta-Iactam antibiotics, penicillins and cephalosporins. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. Shake constituted solution before use. The only adverse effect observed in animal reproductive studies was an increased incidence of abortions in monkeys at 13 times the expected exposure in man. ACS Dobfar SpA, Italy for AstraZeneca UK Limited, Macclesfield, Dosage in Adults with Hepatic Insufficiency : No dosage adjustment is necessary in patients with hepatic insufficiency (see” Special warnings and precautions for use”). 500 mg or 1 g . 1 g IV every 8 hours in the treatment of nosocomial pneumonias, peritonitis, presumed infections in neutropenic patients, septicaemia. E coli meningitis requires antibiotics, such as third-generation cephalosporins (eg, ceftriaxone). Meropenem is also used to treat bacterial meningitis (infection that causes inflammation of the tissue that covers the brain and spinal cord). It has been demonstrated both in vitro and in vivo that meropenem has a Peptostreptococcus magnus, Peptostreptococcus prevotii, Propionibacterium acnes, Propionibacterium avidum, Propionibacterium granulosum. Enterobacter aerogenes, Enterobacter (Pantoea) agglomerans, Enterobacter cloacae, Enterobacter sakazakii, Escherichia coli, Escherichia hermannii, Gardnerella vaginalis, Haemophilus influenzae (including ~-Iactamase positive and ampicillin resistant strains). Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-Iactam antibiotics. MERONEM IV A 30 minute intravenous infusion of a single dose of Meronem in healthy volunteers results in peak plasma levels of approximately 11 mg/ml for the 250 mg dose, 23 mg/ml for the 500 mg dose and 49 mg/ml for the 1 9 dose. Meronem has proved efficacious alone or in combination with other antimic bial agents in the treatment of polymicrobial infections. Imipenem 500mg q8h Meropenem 500mg q8h** Imipenem 1g q8h Meropenem 500mg q6h** Imipenem 750mg q12h Meropenem 500mg q8h** Imipenem 250mg q6h Meropenem 500mg q8h** â¢See full protocol details online for pediatric and renal dosage adjustment recommendations. The clinical efficacy of the drug was stated in all the patients while the bacteriological efficacy amounted to 88.9 per cent. 2018 Aug;37(8):1411-1419. doi: 10.1007/s10096-018-3260-4. This provides an approximate 2000 Jun 15;26(1):65. doi: 10.1016/s0212-6567(00)78610-0. The only metabolite of meropenem is microbiologically inactive. Clin Infect Dis 2016; 63:754. should be used. USA.gov. Cefepime (4th Gen Cephalosporin). cadaveris, Clostridium sordellii, Clostridium butyricum, Clostridium clostridiiformis, Clostridium innocuum, Clostridium subterminale, Clostridium tertium, Eubacterium lentum, Eubacterium aerofaciens, Fusobacterium mortiferum, Fusobacterium necrophorum, There is no experience in paediatric patients with neutropenia or primary or secondary immunodeficiency. Meropenem and imipenem demonstrate good activity against Enterobacteriaceae, including strains producing ESBLs or AmpC (100% for E coli, 99% for other Enterobacteriaceae), meropenem usually being 2 to 4 fold more potent than imipenem [21â23]. Keep all medicines away from children. Show all parts of this monograph; Indications and dose; Unlicensed use; Interactions; Side-effects; Allergy and cross-sensitivity; Pregnancy; Breast feeding; Renal impairment; Monitoring requirements; Effect on laboratory tests; Directions for administration; Medicinal forms; Indications and dose.
2020 meropenem coverage uti